Maintaining Quality of Life With Darolutamide in Nonmetastatic Prostate Cancer

An analysis of the ARAMIS trial looked at quality of life and other outcomes with darolutamide in men with nonmetastatic castration-resistant prostate cancer.

Source: CancerNetwork - June 17, 2019 Category: Cancer & Oncology Authors: Dave Levitan Source Type: news